Abstract Background and Aim For genotype 2 chronic hepatitis C (CHC), the efficacy and
safety of sofosbuvir plus ribavirin therapy (SOF+ RBV) was better than pegylated interferon …

Aim: To evaluate the cost–effectiveness of the novel all-oral direct-acting antiviral regimen
daclatasvir+ asunaprevir (DUAL), versus interferon-based regimens for the treatment of …

Hepatitis C virus (HCV) represents a major public health concern in the United States; often
patients do not develop symptoms until late disease states. Preventative care guidelines …

A one-time HCV test has been recommended for all individuals in the Baby Boomer
generation. National data shows an increase in HCV rates among younger generations …

Introduction: The estimated cost for treatment is calculated in this study as the summation of
utilized materials or medications, consultation (s), lab requests, hospitalization, costs of …

The Asia-Pacific region is home to more than half of the global population and accounted for
62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths due to …

ABSTRACT Background & Aims Prevalence of hepatitis C virus (HCV) infection in the
Netherlands is low (anti-HCV prevalence 0.22%). All-oral treatment with direct acting …

We acknowledge that older data were used in our model, which can be explained by the fact
that we finalized the model inputs before the 2014 CDC statistics 2 were published. The …

Hepatitis C virus (HCV) infection is a major cause of liver cirrhosis, hepatocellular carcinoma
(HCC), and liver-related mortality. The new antiviral drugs, direct acting antivirals (DAA) …